

Madame, Monsieur,

Vous trouverez ci-dessous, la version révisée du deuxième article en premier auteur de mon travail de thèse qui a été soumis au journal *Frontiers in Nutrition* et qui est à ce jour toujours en révision.

Beneficial effects of linseed supplementation on gut inflammation and mucosa-associated microbiota in an active mouse model of Crohn's disease

Claire Plissonneau^{1,2}, Adeline Sivignon², Benoit Chassaing³, Frederic Capel⁴, Vincent Martin^{2,5},
Monique Etienne², Ivan Wawrzyniak⁶, Pierre Chausse⁷, Frederic Dutheil⁸, Guillaume Mairesse⁹,
Guillaume Chesneau⁹, Nathalie Boisseau^{2†} and Nicolas Barnich^{1†*}

¹ Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), UMR 1071 Inserm/Université
Clermont Auvergne; USC-INRAE 2018, Université Clermont Auvergne, CRNH Auvergne, Clermont-
Ferrand, France

² Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et
Pathologiques (AME2P), Université Clermont Auvergne, CRNH Auvergne, Clermont-Ferrand, France

³ Inserm U1016, team "Mucosal microbiota in chronic inflammatory diseases", CNRS UMR 8104,
Université de Paris, Paris, France

⁴ Unité de Nutrition Humaine (UNH), INRAE, Université Clermont Auvergne, CRNH Auvergne,
Clermont-Ferrand, France

⁵ Institut Universitaire de France, Paris, France

⁶ Laboratoire Microorganismes: Génome et Environnement (LMGE), Université Clermont Auvergne,
CNRS, Clermont-Ferrand, France

⁷ Laboratoire de Psychologie Sociale et Cognitive (LaPSCo), CNRS UMR 6024, Université Clermont
Auvergne, Clermont-Ferrand, France

⁸ Laboratoire de Psychologie Sociale et Cognitive (LaPSCo) CNRS UMR 6024, Université Clermont
Auvergne, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU
Clermont-Ferrand, Preventive and Occupational Medicine, WittyFit, Clermont-Ferrand, France ;

⁹ Valorex, La Messayais, 35210 Combournillé

† These authors have contributed equally to this work

* Correspondence:

Nicolas Barnich
nicolas.barnich@uca.fr

Keywords: linseed, mucosa-associated microbiota, adherent-invasive *E.coli*, butyrate,
inflammation.

Abstract

Western diet, rich in lipids and in n-6 polyunsaturated fatty acids (PUFAs), favors gut microbiota alterations and Crohn's disease (CD). The aim of this study was to assess the effects of rebalancing the n-6/n-3 PUFA ratio in CEABAC10 transgenic mice that mimic CD. Mice in individual cages with running wheels were randomized in three diet groups for 12 weeks: high-fat diet (HFD), HFD + linseed oil (HFD-LS-O) and HFD + extruded linseed (HFD-LS-E). Then, they were orally challenged once with the Adherent-Invasive *Escherichia coli* (AIEC) LF82 pathobiont, followed by evaluation of body composition, mucosa-associated microbiota composition, plasma lipopolysaccharides, fecal short-chain fatty acid production, and inflammatory marker levels at day 0 and day 6 post-challenge. After 12 weeks of diet, total energy intake, body composition and intestinal permeability were not different in the three groups. After the AIEC-induced intestinal inflammation, fecal lipocalin-2 concentration was lower at day 6 in n-3 PUFAs supplementation groups (HFD-LS-O and HFD-LS-E) compared to HFD. Thus, n-3 PUFAs may have limited the AIEC-induced intestinal inflammation. Moreover, fecal lipocalin-2 concentration was negatively correlated with the voluntary physical activity level. Analysis of the mucosa-associated microbiota composition showed that the abundance of *Prevotella*, *Paraprevotella*, *Ruminococcus* and *Clostridiales* was higher in the HFD-LS-E group than in the HFD and HFD-LS-O groups. Butyrate levels also were higher in the HFD-LS-E group and were correlated with the Firmicutes/Proteobacteria ratio. This study demonstrates that n-3 PUFA supplementation (especially HFD-LS-E) had a beneficial health effect in an active mouse model of CD susceptibility. Additional studies are needed to better understand the matrix influence in the linseed supplementation effect.

1 Introduction

Crohn's disease (CD) is an inflammatory bowel disease. Although, the cause is unknown, many factors have been implicated in this pathology, such as genetic predisposition, environmental factors, immune system deregulation, and intestinal microbiota alterations (1). Indeed, in patients with CD, bacterial diversity is reduced: members of the Firmicutes phylum, such as *Faecalibacterium prausnitzii*, are decreased, whereas members of the Bacteroidetes and Proteobacteria phyla, especially *Enterobacteriaceae* among which *Escherichia coli* (2–6), are increased. However, it is not clear whether this dysbiosis is a cause and/or a consequence of CD. At the subspecies level, adherent-invasive *E. coli* (AIEC) has been detected more frequently in ileal samples from patients with CD than in healthy controls (7). AIEC can adhere to and invade intestinal epithelial cells, and they also survive and replicate within macrophages (7,8). Studies in CD animal models suggest an important role of AIEC in gut inflammation induction and/or maintenance (9–11). AIEC strains bind to mannosylated receptors, such as carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) that is abnormally expressed at the enterocyte surface in patients with CD (12). AIEC colonization is CEACAM6- and type 1 pili-dependent and promotes intestinal inflammation (9), as observed in CEABAC10 transgenic mice that express human CEACAM6.

In CEABAC10 transgenic mice, the Western diet, which is considered a risk factor for CD development (13), increases AIEC capacity to colonize the gut mucosa, and then to trigger inflammation (14,15). The Western diet is poor in fibers and rich in total fat, especially saturated fatty acids and n-6 polyunsaturated fatty acids (PUFAs), and in refined sugars and animal proteins. Animal models of diet-induced obesity and metabolic disorders demonstrated that high fat/high sugar diets increase the total fat mass (especially visceral fat mass), enhance metabolic disorders, favors chronic low grade inflammation, and alter gut microbiota composition (14–17). Thus, environmental factors, including long-term lifestyle habits, which influence gut microbiota community and diversity (18,19),

may trigger CD, and could be a relevant target in its management. In developed Western countries, n-3 PUFA intake is much lower than that of n-6 PUFAs (20,21). However, n-3 PUFAs exert beneficial effects on body composition, lipid profile, and the inflammation state in metabolic diseases (22,23). They can also improve the intestinal barrier function and integrity (24) and influence gut microbiota composition in these metabolic pathologies (25–27). A supplementation of n-3 PUFAs and a rebalance of n-6 PUFA intake could be a relevant strategy to manage chronic inflammation and dysbiosis in the remission/inactive phases of CD. For decades, marine products have been mainly used to evaluate the impact of n-3 PUFA supplementation, but currently, linseed, rich in α -linolenic acid (ALA, C18:3 n-3 PUFAs), is increasingly studied (26). Linseed is a plant rich in ALA, lignans, especially secoisolariciresinol diglucoside (SDG), and other bioactive components. Therefore, besides n-3 PUFA beneficial effects, linseed, a matrix with fatty acids, fibers, lignans and other bioactive components, may have a therapeutic effects on human health and CD prevention (28,29).

Moreover, regular physical exercise could be a complementary therapy to the rebalance of the n-6/n-3 PUFA ratio due to its anti-inflammatory effects and its capacity to decrease total fat mass, including visceral adipose tissue (30–32). Indeed, in patients with CD, the ratio of (intra)-abdominal subcutaneous adipose tissue to total adipose tissue is significantly higher than in healthy controls (33). In CD, this visceral fat mass, called “creeping fat”, surrounds the small intestine and colon and is metabolically active (34,35). It leads to the release of pro-inflammatory mediators, such as tumor necrosis factor alpha (TNF- α) and interleukine-6 (IL-6)(36,37). Studies in animal models of intestinal inflammation highlighted the anti-inflammatory effect of voluntary exercise and spontaneous physical activity (38,39). Physical activity also may prevent intestinal injury following bacterial infection and/or exposure to bacterial components (40), and intestinal damage caused by the Western diet (41,42).

Therefore, the aim of this study was to assess the preventive effect of two forms of linseed supplementation (oil and extruded linseed) by rebalancing the n-6/n-3 PUFA ratio in an active mouse model of CD susceptibility fed a high fat diet (HFD). The study focused on the effects on body composition, AIEC-induced intestinal inflammation, and mucosa-associated microbiota. Two forms of linseed supplementation were used to determine whether the matrix could modify the biological effects (43,44).

2 Material and methods

2.1 Animals

FVB/N female and heterozygous CEABAC10 transgenic male mice (Charles River Laboratories) were mated in specific pathogen-free conditions in the animal care facility of the University Clermont Auvergne (Clermont-Ferrand, France). At 4 weeks of age, animals were weaned and genotyped. Eight-week-old CEABAC10 males (n = 48) were selected and randomly assigned to the three groups: HFD (n = 16), HFD + linseed oil (HFD-LS-O; n = 16), and HFD + extruded linseed (HFD-LS-E; n = 16) (**Figure 1**). Animals were housed in individual cages with reversed light-dark cycle in a temperature-controlled room (20 \pm 2°C). All animal procedures were approved by the local ethics committee (APAFIS 19400-2019022211242750).

2.2 Spontaneous physical activity

Mice (HFD, HFD-LS-E and HFD-LS-O groups) performed voluntary wheel running in their individual cage. To measure the covered distance, each wheel was monitored with a magnet and a

sensor connected to a microcontroller digital input-output card (PIC18 4550 MICROCHIP). A card was programmed specifically for this use and allowed to record each passage of the magnet in front of the sensor. The information was sent back to a computer for processing and storage using a specific program written in G language (LABVIEW National Instrument). Data analysis with MATLAB (MathWorks®, CA, USA) allowed the calculation of the travelled distance (km). Exercise was recorded continuously, and cages were visually checked at least five times/week.

2.3 Diets

The diets were prepared by INRAE (Jouy-en-Josas, France). During the entire study, the HFD (i.e. a high fat/high sucrose diet as a paradigm of the Western diet) contained 43.3% of fat, 39.4% of carbohydrates and 17.3% of proteins, for a total energy amount of 468.40 kcal/100g and a n-6/n-3 PUFA ratio of 14.80 (**Table 1**). To prepare the oil or extruded linseed-supplemented diets, the n-6/n-3 PUFA ratio, the macronutrient percentage, and the total kcal/100 g were considered (**Table 1**). The diet of the HFD-LS-O group contained 41% of fat, 41% of carbohydrates and 18% of proteins, for a total energy amount of 468.40 kcal/100g and a n-6/n-3 PUFA ratio of 3.3. The diet of the HFD-LS-E group was similar, but included extruded linseed (Tradilin, Patent n°FR1760984). It contained 41% of fat, 41.7% of carbohydrates, and 18% of proteins, for a total energy amount of 460.44 kcal/100g and a n-6/n-3 PUFA ratio of 3 (**Table 1**). The calculated diet compositions are listed in **Tables 1 and 2**. Extruded linseed is a matrix that includes other components listed in **Figure 2**.

2.4 Study design

Groups followed their own diet (HFD, HFD-LS-O and HFD-LS-E) during the entire protocol. Pair feeding was performed throughout the protocol to ensure that groups consumed the same food quantity. After 12 weeks, dextran sulfate sodium (1%) (MP biomedical, Irvin, CA, USA) was added to the drinking water. After three days, all mice were orally challenged once with the AIEC LF82 strain (10^9 bacteria), isolated from a patient with CD. The AIEC LF82 strain was grown in LB broth (Condalab, Madrid, Spain), without agitation, at 37°C for 24h. Seven days after, mice were euthanized by cervical dislocation (**Figure 1**).

2.5 Weight and body composition

Body composition (weight, fat mass and free-fat mass) was evaluated using an EchoMRI device (EchoMRI Medical System, Houston, TX, USA) at week 1, 6 and 12 before the oral challenge with the AIEC LF82 strain. Body weight was measured three times per week using a standard scale during the first 12 weeks, and then on infection day and at day 1, 3 and 6 post-challenge. Mesenteric and epididymal total adipose tissues were weighted post-mortem (day 7 post-challenge).

2.6 Polyunsaturated fatty acids in mesenteric adipose tissue

Mesenteric adipose tissue samples (15-20 mg) were homogenized in 2:1 (v/v) chloroform/methanol solution using ceramic beads and a Minilys system (Bertin instruments, Ozyme, Montigny-le-Bretonneux FRANCE) according to the method described by Folch et al (45). Total lipids were isolated for fatty acid methylation analysis as described previously (46) using gas chromatography and a Finnigan Trace GC Ultra instrument (Waltham, MA, USA).

154 2.7 Inflammation markers

155 Feces were collected at day 1, day 3 and day 6 post-AIEC challenge. Samples were weighted,
156 and then homogenized (without marbles) in phosphate buffer saline (PBS) for 15 min before
157 centrifugation at 12000 rpm, at 4°C for 10 min. Lipocalin-2 was quantified with an ELISA kit
158 (Biotechne, Minneapolis, MN, USA) in duplicate.

159 LPS activity in plasma samples was evaluated, in duplicate, using HEK-Blue-mTLR4 cells
160 (InvivoGen, San Diego, CA, USA). Briefly, 180 µL of cell suspension (1.4×10^4 cells per mL of HEK-
161 Blue Detection medium) (InvivoGen, San Diego, CA, USA) was added to 20 µL of each diluted (1:10)
162 plasma sample. LPS (InvivoGen, San Diego, CA, USA) was used as positive control and to calculate
163 the standard range. Plates were incubated at 37°C in 5% CO₂ for 24 h, and alkaline phosphatase activity
164 was measured at 620 nm.

165 2.8 Fecal short-chain fatty acid

166 Weighted fecal samples were reconstituted in 200 µL MilliQ® water, homogenized, incubated
167 at 4°C for 2h, and then centrifuged at 12 000 g at 4°C for 15 min. Supernatants were weighted, saturated
168 phosphotungstic acid (100 µL for 1 g of fecal content) was added, and samples were incubated at 4°C
169 overnight. After centrifugation, short chain fatty acid (SCFA) concentrations (including butyrate,
170 propionate and acetate) were determined by gas chromatography (Nelson 1020, Perkin-Elmer, St
171 Quentin en Yvelines, France). Briefly, chromatographic separation was achieved on DB-FFAP
172 columns (30 m × 250 µm, 0.25 µm). The injector temperature was 250°C and the injection volume was
173 1 µL. The initial oven temperature was 100 °C, and then was increased to 250 °C (10 °C/min) and held
174 for 5 min. The carrier gas was helium at a constant flow of 7 mL/min. Samples were injected using the
175 split mode at a ratio of 10:1. Detection was performed with a flame ionization detector (FID).

176 2.9 Intestinal permeability: FITC-dextran

177 *In vivo* intestinal permeability was measured using FITC-dextran 4 kDa (FD4, Sigma, St. Louis,
178 MO) at week 12 of the diet. Mice were orally challenged with 7.5 mg FD4 diluted in PBS for 5 h before
179 blood collection. Serum was separated by centrifugation (5000 g, 30 min) and FITC concentration was
180 determined by fluorescence measurement.

181 2.10 Microbiota composition analyses

182 For genomic DNA extraction, mouse colon samples were lysed in proteinase K at 56°C in a
183 shaking incubator overnight. DNA was extracted using the Nucleospin® Tissue kit (Macherey-Nagel,
184 Germany). DNA concentration was determined with a Qubit™ fluorometer (Invitrogen), and the
185 DNA quality was evaluated with a NanoDrop™ (Thermo Scientific) spectrophotometer (260/280 and
186 260/230 ratio). Region V4 of the 16S rRNA gene was PCR-amplified using forward and reverse
187 primers that were designed with the Golay error-correcting scheme and used to tag PCR products from
188 individual samples (47). The sequence of the composite forward primer 515F was: 5'-
189 AATGATACGGCGACCACCGAGATCTACACGCTXXXXXXXXXXXXTATGGTAATTGTGTGY
190 CAGCMGCCGCGGTAA-3'. The italicized sequence represents the 5' Illumina adapter, the 12X
191 sequence is the Golay barcode, the bold sequence is the primer pad, the italicized and bold nucleotide

is the primer linker, and the underlined sequence is the conserved bacterial sequence. The sequence of the reverse primer 806R was: 5'-CAAGCAGAAGACGGCATACTGAGATAGTCAGCCAGCCGGACTACNVGGGTWTCTAAT-3'.

The italicized sequence is the 3' reverse complement sequence of the Illumina adapter, the bold sequence is the primer pad, the italicized and bold nucleotides are the primer linker, and the underlined sequence is the conserved bacterial sequence. PCR mixtures included the Hot Master PCR mix (Quantabio, Beverly, MA, USA), 0.2 μ M of each primer, and 10-100 ng of template. The reaction conditions were: 3 min at 95°C, followed by 30 cycles of 45s at 95°C, 60s at 50°C and 90s at 72°C on a BioRad thermocycler. PCR products were purified with Ampure magnetic purification beads (Agencourt, Brea, CA, USA) and visualized by gel electrophoresis. Products were then quantified (BIOTEK fluorescence spectrophotometer) using the Quant-iT PicoGreen dsDNA assay. A master DNA pool was generated from the purified products mixed in equimolar ratios. The pooled products were quantified using the Quant-iT PicoGreen dsDNA assay and then sequenced using an Illumina MiSeq sequencer (paired-end reads, 2 x 250 bp) at Cornell University, Ithaca.

16S rRNA sequences were analyzed using QIIME2—version 2019 (48). Sequences were demultiplexed and quality filtered using the Dada2 method (49) with QIIME2 default parameters in order to detect and correct Illumina amplicon sequence data, and a table of Qiime 2 sequence variants (SVs) was generated. A tree was next generated, using the align-to-tree-mafft-fasttree command, for phylogenetic diversity analyses, and alpha and beta diversity analyses were computed using the core-metrics-phylogenetic command. Principal coordinate analysis (PCoA) plots were used to assess the variation between the experimental groups (beta diversity). For taxonomy analysis, features were assigned to operational taxonomic units (OTUs) with a 99% threshold of pairwise identity to the Greengenes reference database 13_8 (50). All sequencing raw data have been deposited in European Nucleotide Archive (ENA) under accession number PRJEB48648.

2.11 Statistical analysis

All statistical analyses were performed with the Statistica software (version 12). Data were presented as the mean \pm standard deviation (SD). Normal data distribution was tested using the Kolmogorov–Smirnov test, and the homogeneity of variance with the F-test. Then, a *t*-test or a Mann Whitney test was performed to compare the two supplemented groups (HFD-LS-O + HFD-LS-E pooled together) vs. HFD. A one-way ANOVA or a Kruskal-Wallis test was used to compare post-mortem values in the three groups. One-way ANOVA with repeated measures was used to determine group (G) effect, time (T) effect, and T*G interactions. For repeated measures, in the absence of normal distribution or variance homoscedasticity, data were first log transformed. The Newman-Keuls post-hoc test was used for all ANOVA analyses. Categorical data were compared with the Chi-square test. Finally, Spearman correlations were used to test relationships between variables. Differences were considered significant when p-values <0.05.

3 Results

3.1 Body composition in an active mouse model that mimics CD susceptibility.

Food intake (g and Kcal) and spontaneous physical activity (average distance per day) were not different in the three groups during the 12 weeks (**Figure 3A-B**), as well as body weight changes and weight gain (assessed as fat mass and fat-free mass) (**Figure 3C-D**). Similarly, no difference was observed in the percentage of mesenteric and epididymal adipose tissues relative to the total fat mass (**Figure 3E-F**). Nevertheless, the linoleic acid (C18:2 n-6)/ α -linolenic acid (C18:3 n-3) (LA/ALA) ratio in the mesenteric adipose tissue was significantly decreased in both linseed supplementation groups (HFD-LS-O and HFD-LS-E) compared with the HFD group (**Figure 3G**).

3.2 AIEC-induced inflammation.

Weight monitoring at day 0 (just before the challenge) and at day 1, 3 and 6 after the challenge did not find any difference in the three groups, indicating that the linseed supplementation did not influence AIEC-induced weight loss (**Figure 4A**). Quantification of fecal lipocalin-2 by ELISA, a non-invasive, sensitive, dynamic, stable and cost-effective biomarker to monitor intestinal inflammation in mice (51), did not show any significant difference in the HFD and HFD-LS-O/HFD-LS-E groups at day 1 post-challenge, indicating a similar level of intestinal inflammation in the three groups at this time point. At day 6, fecal lipocalin-2 levels were significantly higher in the HFD group than in the HFD-LS-O/HFD-LS-E groups, suggesting that linseed supplementation (both forms) limited AIEC-induced intestinal inflammation (**Figure 4B**). Fecal lipocalin-2 levels at day 6 were similar in the HFD-LS-O (pink triangles) and HFD-LS-E (green circles) groups, indicating that the limiting effect was independent of the matrix. The negative correlation ($p < 0.05$) between fecal lipocalin-2 concentrations and level of physical activity (mean distance in km per day) (**Figure 4C**) suggested that physical activity may contribute to the limitations of AIEC-induced intestinal inflammation.

As intestinal inflammation can lead to increased intestinal permeability (leaky gut), which is a major problem in inflammatory bowel disease, intestinal permeability was evaluated *in vivo* by measuring FITC-dextran 4kDa (exogenous molecule provided by oral gavage) in serum (at week 12) and lipopolysaccharides (LPS; bacterial component naturally present in the microbiota) in plasma (at day 7 post-challenge). FITC-dextran and LPS levels were comparable in the three groups (**Figure 4D-E**), indicating that the linseed supplementation did not have a major effect on the intestinal barrier function.

3.3 Intestinal mucosa-associated microbiota diversity and composition.

At day 7 after the AIEC challenge, analysis of the colon mucosa-associated microbiota composition by 16S rRNA sequencing showed that the α -rarefaction curve contained significantly more OTUs in the HFD-LS-E group ($p < 0.05$) (**Figure 5A**). This indicated that the addition of extruded linseed to the HFD diet had a beneficial effect on microbial species. Moreover, the number of observed OTUs was significantly increased in the HFD-LS-E group compared with the HFD and HFD-LS-O groups (**Figure 5B**). The α -diversity, represented by the Shannon index, tended to increase in the HFD-LS-E group ($p = 0.10$) (**Figure 5C**). Evenness was comparable among groups (**Figure 5D**). Conversely, the phylogenetic diversity was significantly increased ($p < 0.01$) in the HFD-LS-E group compared with the HFD and HFD-LS-O groups (**Figure 5E**). The β -diversity analysis by principal coordinate analysis of the weighted and unweighted UniFrac distance matrices showed that colon microbiota composition was changed only when using unweighted UniFrac data in the HFD-LS-E group compared with the HFD and HFD-LS-O groups ($p < 0.05$) (**Figure 5F-G**).

Concerning the abundance of specific microbiota phyla in the colon mucosa, Firmicutes tended to increase ($p=0.064$) in both supplemented groups (HFD-LS-O and HFD-LS-E) (**Figure 6A**). Compared with the HFD group, linseed supplementation increased the Firmicutes/Proteobacteria ratio ($p=0.03$) (**Figure 6B**). The analysis of composition of microbiomes (ANCOM) highlighted significant group differences for specific mucosa-associated microbiota species (**Figure 6C-F**). Indeed, in the HFD-LS-E group, the relative abundance of *Clostridiales* spp., *Paraprevotella* spp. and *Prevotella* spp. was significantly increased compared with the HFD and HFD-LS-O groups ($p < 0.05$) (**Figure 6C, D and F**) and that of *Ruminococcus* spp. compared with the HFD group ($p < 0.05$) (**Figure 6F**).

SCFAs produced by the microbiota were quantified in fecal samples. No difference was found among groups concerning acetate, butyrate, propionate and total SCFAs concentrations (**Table 3**). Butyrate, a major SCFA (due to its fermentative activity and beneficial effects at the intestinal level), tended to increase only in the HFD-LS-E group (**Figure 7A**), in line with the observed increased percentage of SCFA-producing *Firmicutes* in this group. When only mice in which fecal butyrate could be detected were considered, their percentage was significantly higher in the HFD-LS-E group ($p < 0.0001$) (**Figure 7B**). Furthermore, the level of fecal butyrate was positively correlated ($p=0.0163$) with the mucosa-associated Firmicutes/Proteobacteria ratio (**Figure 7C**).

4 Discussion

The aim of this study was to determine whether two different forms of linseed supplementation (oil and extruded seeds as specific matrix) to rebalance n-6/n-3 PUFA ratio in a high-fat diet have a preventive effect in active mice that mimic CD susceptibility. In our experimental conditions that included spontaneous physical activity, the two linseed forms appear to act beneficially on AIEC-induced intestinal inflammation, but only HFD-LS-E modulated the gut mucosa-associated microbiota diversity, increased the abundance of *Clostridiales*, *Prevotella* and *Ruminococcus* bacteria, and enhanced the production of beneficial metabolites, such as fecal butyrate.

In the present study, we chose to use CEABAC10 transgenic mice fed a HFD and challenged with AIEC because we previously reported that this mouse model mimics what occurs in patients with CD (14,15). Indeed, in these mice, HFD induces gut microbiota composition changes and alters the host homeostasis by promoting AIEC encroachment (14). In addition, spontaneous physical activity in this model decreases total fat mass, improves glucose metabolism, and promotes healthy gut microbiota composition changes, with an increase in SCFA-producing species belonging to the *Oscillospira* and *Ruminococcus* genera, linked to higher fecal levels of propionate and butyrate (39). Western diet is characterized by low fiber and high fat intakes, especially n-6 PUFAs and saturated and trans fatty acids, and this could explain the increase of total fat mass and chronic low-grade inflammation, and the gut microbiota dysbiosis (20,52). Therefore, we evaluated the impact of spontaneous physical activity level combined with n-6/n-3 PUFA ratio rebalancing (using linseed, rich in n-3 PUFAs) on gut mucosa-associated microbiota in HFD-fed CEABAC10 mice before and after AIEC-induced inflammation. Our results suggest that linseed supplementation (whatever the matrix) may limit AIEC-induced intestinal inflammation as shown by the lower fecal lipocalin-2 concentrations (a sensitive and non-invasive inflammation biomarker (51)) in the supplemented groups, without affecting the intestinal permeability. It is known that n-3 PUFAs have anti-inflammatory properties, particularly after stimuli that promote inflammation (53). Indeed, after 12 weeks of supplementation, n-3 PUFAs should have been converted to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the active metabolic n-3 PUFA derivatives. These derivatives should have been incorporated into the cell membrane phospholipids, to be released and converted into "specialized pro-resolving mediators", in order to indirectly inhibit the NF- κ B pathway, in response to acute inflammation (54), as the AIEC

exposure in this study. We hypothesized that n-3 PUFA intake from linseed, independent of form intake (HFD-LS-O and HFD-LS-E groups), may have limited AIEC-induced inflammation. Long-term n-3 PUFA intake could be interesting for preventing acute intestinal inflammation, and for improving the resolution of acute inflammation. As CD is characterized by acute phases with inflammation, and periods of remission, our results also suggest that in the long term, n-6/n-3 PUFA rebalancing may decrease the susceptibility to relapse during re-exposure to AIEC and prolong periods of remission.

As CD is associated with detrimental changes in the microbiota composition and function, we then evaluated the impact of the two linseed forms (HFD-LS-O and HFD-LS-E) on the intestinal mucosa-associated microbiota in active HFD-fed CEABAC10 mice. In addition, we recently demonstrated in a cohort of 102 patients with Crohn's disease that the presence of the AIEC pathobiont in the mucosa, but not in stool, correlates with the inflammatory state (55). Therefore, we decided to focus on the mucosa-associated microbiota rather than on the luminal and/or fecal microbiota. HFD-LS-E modulated β -diversity and tended to increase α -diversity (i.e. Shannon index). Moreover, OTUs were significantly increased in the HFD-LS-E group compared with the HFD and HFD-LS-O groups, demonstrating a greater impact of HFD-LS-E supplementation on the gut mucosa-associated microbiota diversity. Thus, extruded linseed, as specific matrix that includes different components (e.g. lignans and especially SDG and other bioactive components (56)) had the major effect on the mucosa-associated microbiota compared.

Interestingly, at the phylum level, the Firmicutes/Proteobacteria ratio was increased in both linseed-supplemented groups. This is in favor of a less colitogenic microbiota, because Firmicutes contain many beneficial SCFA-producing species, whereas Proteobacteria have pro-inflammatory properties (57–59). The analysis of specific features of the mucosa-associated microbiota highlighted several differences in the three groups. First, *Clostridiales* spp. abundance was significantly increased in the HFD-LS-E group compared with the HFD and HFD-LS-O groups. Moreover, HFD-LS-E also induced an increase of the *Ruminococcus*, *Prevotella* and *Paraprevotella* genera. *Clostridiales* are increased in patients with obesity (60), but linseed influence on *Clostridiales* abundance is not known, and several studies even reported a *Clostridiales* decrease after fish oil supplementation (25,61,62). Conversely, Zhu et al. showed an increase of *Clostridiales* in mice after gavage of EPA and DHA) (60 mg. Therefore, *Clostridiales* abundance might be influenced by the n-3 PUFA type and dose (63). Interestingly, *Paraprevotella* is a succinate producer and may play a role in energy metabolism. To our knowledge, only few studies assessed *Paraprevotella* abundance in humans associated with physical activity, n-3 PUFA intake, and linseed supplementation. *Paraprevotella* abundance might be positively associated with lower body mass index, lower Mediterranean diet adherence, and lower physical activity levels (64). Moreover, *in vitro* experiments suggests that its abundance may be increased in sheep rumen after exposure to n-3-PUFAs (n-3 docosapentaenoic acid, EPA and DHA) (65). *Ruminococcus* is a genus that includes butyrate-producing species, and is less abundant in patients with CD (66). Li et al. reported the *Ruminococcus* genus increase after linseed oil supplementation (67). This effect may be due to other linseed components than n-3 PUFAs. Indeed, linseed includes ~1% of SDG, phytoestrogens that are metabolized by the gut microbiota to secoisolariciresinol (SECO), and then to enterodiol and enterolactone that are bioactive polyphenolic components (68). The gut microbiota diversity and composition seem to be linked to the production (69) and excretion of enterolactone and enterodiol (70,71). The relationship between SDG and gut microbiota has been investigated mainly to evaluate the role of bacterial species in SDG conversion (69,72,73). Some *Ruminococcus* species seem to play an important role in SDG biotransformation, such as *Ruminococcus gnavus* (43,74), *Ruminococcus bromii* and *Ruminococcus lactaris* (69), or even *Ruminococcus albus* and *Ruminococcus flavefaciens* (73). Fuentealba et al. compared the effect of linseed flour and whole linseed on the digestive process *in vitro*. They found that SCFA production

was increased by linseed flour due to a greater fermentation process (75). Thus, linseed flour may increase SDG release and enterodiol production compared with whole linseed. A recent study on the impact of whole linseed, linseed oil, or SDG supplementation in female mice (43) found that whole linseed is necessary for the complete SDG metabolization by the gut microbiota. Indeed, although the gut microbiota responds to specific dietary inputs (e.g. *R. gnavus* in a SDG-supplemented diet), the cooperative activities of a diverse microbiota are necessary to process linseed components. The authors also suggested that other unknown linseed components may be essential to optimize SDG digestion and conversion to enterodiol and enterolactone (43). In 1996, Rickard *et al.* also observed in rats that SDG is not entirely metabolized, unlike whole linseed (44). They hypothesized that another lignan precursor may exist in linseed. The *R. gnavus* *gus* gene encodes β -glucuronidase, an enzyme that plays a major role in the absorption and enterohepatic circulation of aglycone residues, such as lignans. Beaud *et al.* showed that SDG may stimulate *R. gnavus* growth by acting as a substrate (74). Only one randomized, placebo-controlled cross-over study analyzed the human gut microbiota composition following enterolactone and enterodiol supplementation (71), and found that enterolactone and enterodiol were linked to the gut microbiota composition. Moreover, the excretion of enterolactone and enterodiol was positively correlated with *Ruminococcaceae* abundance (71). The authors also found transcriptomic differences between low and high enterolactone excretors, and suggested that enterolactone or other activities associated with the gut microbiota modulate the responses to a lignan-supplemented diet (71). On the other hand, *R. gnavus* may be associated with CD by producing inflammatory polysaccharides (76). More studies are needed to precisely determine *Ruminococcus* role, especially of *R. gnavus*, in CD.

We also found that in the HFD-LS-E group, the relative abundance of *Prevotella*, which is present in fiber-rich diets and carbohydrate-rich diets, was increased. The fibers and lignans contained in extruded linseed may have contributed to this increase. Schogor *et al.*, showed that *in vitro* and *in vivo*, *Prevotella* spp. may contribute to SDG conversion to SECO in the rumen of animals (73). Consistent with our data, Li *et al.* found an increase in *Prevotella* in the rumen of animals after a diet supplemented in linseed oil and propionate precursors (67). The linseed supplementation, as a matrix, may have stimulated *Prevotella* spp. growth. We previously reported that *Prevotella* increases in obese-induced Wistar rats after a 12-week high-intensity interval-training program (46). Petersen *et al.* found that *Prevotella* abundance increase in the microbiota of competitive cyclists is correlated with the mean exercise time per week (77). Conversely, here, we did not observe any correlation between mean spontaneous exercise distance and *Prevotella* abundance. This could be explained by the fact that mice performed spontaneous activity, and it has been reported that spontaneous and imposed exercise modulate differently the gut microbiota (78). Thus, it could be relevant in the future to assess the effect on *Prevotella* abundance of a controlled exercise modality, such as moderate intensity continuous training (31) or high intensity interval training (46), combined with HFD-LS-E supplementation.

Our study shows that in active CEABAC10 mice challenged with AIEC to mimic CD susceptibility, rebalancing the n-6/n-3 PUFA ratio of the HFD by linseed supplementation, as a matrix, promotes colon mucosa-associated microbiota composition changes. The abundance of butyrate producers, such as the *Clostridiales* order and *Ruminococcus* genus that are considered health-related bacteria, was increased in the HFD-LS-E group. These findings suggest that in the long term, the microbiota modulations induced by extruded linseed supplementation may prevent the onset of chronic pathologies that involve dysbiosis in active individuals, and may extend the remission period in patients with CD.

413 **5 Conflict of Interest**

414 The authors declare that the research was conducted in the absence of any commercial or financial
415 relationships that could be construed as a potential conflict of interest.

416 **6 Author Contributions**

417 Conceptualization, N.B. (Nicolas Barnich) and N.B. (Nathalie Boisseau); data curation, C.P.; formal
418 analysis, C.P. and B.C.; funding acquisition, N.B. (Nicolas Barnich) and N.B. (Nathalie Boisseau);
419 investigation, C.P., A.S., F.C., B.C., I.W., V.M., P.C., F.D., M.E., N.B. (Nicolas Barnich), and N.B.
420 (Nathalie Boisseau); methodology, A.S., F.C., N.B. (Nicolas Barnich), and N.B. (Nathalie Boisseau);
421 project administration, N.B. (Nicolas Barnich) and N.B. (Nathalie Boisseau); supervision, N.B.
422 (Nicolas Barnich) and N.B. (Nathalie Boisseau); validation, N.B. (Nicolas Barnich) and N.B. (Nathalie
423 Boisseau); visualization, C.P.; writing—original draft, C.P.; writing—review and editing, C.P., A.S,
424 B.C., F.C., V.M., I.W., F.D., P.C., M.E., G.M., G.C., N.B. (Nicolas Barnich), and N.B.

425 **7 Funding**

426 This study was mainly funded by grants from Valorex. The authors are also supported by the Ministère
427 de la Recherche et de la Technologie (M2iSH and AME2P Unit), Inserm (UMR 1071), INRAE (USC-
428 2018), and by the French government IDEX-ISITE initiative 16-IDEX-0001 (CAP 20-25), I-SITE
429 project (CAP 2025) of the University of Clermont Auvergne and the national program “Microbiote”
430 from INSERM. Benoit Chassaing’s laboratory is supported by a Starting Grant from the European
431 Research Council (ERC) under the European Union’s Horizon 2020 research and innovation
432 programme (grant agreement No. ERC-2018-StG- 804135), a Chaire d’Excellence from IdEx
433 Université de Paris - ANR-18-IDEX-0001, an Innovator Award from the Kenneth Rainin Foundation
434 and the national program “Microbiote” from INSERM.

435 **8 Acknowledgments**

436 We thank the Installation Experimental de Nutrition (IEN) for animal care (INRAE, Theix, France). The
437 authors thank the Genom’IC sequencing platform.

438 **9 Data Availability Statement**

439 Unprocessed 16S sequencing data are deposited in the European Nucleotide Archive under accession
440 numbers PRJEB48648

441

442

443

444

445

446

447

448 **10 References**

- 449 1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established
450 and evolving therapies. *Lancet Lond Engl.* 2007 May 12;369(9573):1641–57.
- 451 2. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al. Culture
452 independent analysis of ileal mucosa reveals a selective increase in invasive *Escherichia coli* of novel
453 phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. *ISME J.* 2007
454 Sep;1(5):403–18.
- 455 3. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced
456 diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. *Gut.* 2006
457 Feb;55(2):205–11.
- 458 4. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of
459 the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. *Gut.* 2003
460 Feb;52(2):237–42.
- 461 5. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of
462 *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis.* 2009 Aug;15(8):1183–9.
- 463 6. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and
464 composition of the mucosal flora in patients with inflammatory bowel disease. *J Clin Microbiol.*
465 2005 Jul;43(7):3380–9.
- 466 7. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, et al.
467 Presence of adherent *Escherichia coli* strains in ileal mucosa of patients with Crohn’s disease.
468 *Gastroenterology.* 1998 Dec;115(6):1405–13.
- 469 8. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A-L, Barnich N, et al. High
470 prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn’s disease.
471 *Gastroenterology.* 2004 Aug;127(2):412–21.
- 472 9. Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CHF, Stanners CP, et al. Crohn’s
473 disease adherent-invasive *Escherichia coli* colonize and induce strong gut inflammation in transgenic
474 mice expressing human CEACAM. *J Exp Med.* 2009 Sep 28;206(10):2179–89.
- 475 10. Chassaing B, Koren O, Carvalho FA, Ley RE, Gewirtz AT. AIEC pathobiont instigates
476 chronic colitis in susceptible hosts by altering microbiota composition. *Gut.* 2014 Jul;63(7):1069–80.
- 477 11. Schmitz JM, Tonkonogy SL, Dogan B, Leblond A, Whitehead KJ, Kim SC, et al. Murine
478 Adherent and Invasive *E. coli* Induces Chronic Inflammation and Immune Responses in the Small
479 and Large Intestines of Monoassociated IL-10-/- Mice Independent of Long Polar Fimbriae Adhesin
480 A. *Inflamm Bowel Dis.* 2019 Apr 11;25(5):875–85.
- 481 12. Barnich N, Carvalho FA, Glasser A-L, Darcha C, Jantscheff P, Allez M, et al. CEACAM6
482 acts as a receptor for adherent-invasive *E. coli*, supporting ileal mucosa colonization in Crohn
483 disease. *J Clin Invest.* 2007 Jun;117(6):1566–74.

484 13. Chapman-Kiddell CA, Davies PSW, Gillen L, Radford-Smith GL. Role of diet in the
485 development of inflammatory bowel disease. *Inflamm Bowel Dis*. 2010 Jan;16(1):137–51.

486 14. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, et al. Western diet
487 induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring
488 AIEC colonisation. *Gut*. 2014 Jan;63(1):116–24.

489 15. Agus A, Denizot J, Thévenot J, Martinez-Medina M, Massier S, Sauvanet P, et al. Western
490 diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli
491 infection and intestinal inflammation. *Sci Rep*. 2016 Jan 8;6:19032.

492 16. Cani, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut
493 microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and
494 diabetes in mice. *Diabetes*. 2008 Jun;57(6):1470–81.

495 17. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen Y-Y, et al.
496 High-fat diet determines the composition of the murine gut microbiome independently of obesity.
497 *Gastroenterology*. 2009 Nov;137(5):1716-1724.e1-2.

498 18. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health.
499 *BMJ*. 2018 Jun 13;361:k2179.

500 19. Rinninella E, Cintoni M, Raoul P, Lopetuso LR, Scaldaferri F, Pulcini G, et al. Food
501 Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. *Nutrients*. 2019
502 Oct 7;11(10):E2393.

503 20. Simopoulos AP. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk
504 for Obesity. *Nutrients*. 2016 Mar 2;8(3):128.

505 21. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. *Poult Sci*. 2000
506 Jul;79(7):961–70.

507 22. Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb
508 J, et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. *J Nutr*
509 *Biochem*. 2018 Aug;58:1–16.

510 23. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or
511 pharmacology? *Br J Clin Pharmacol*. 2013 Mar;75(3):645–62.

512 24. Lam YY, Ha CWY, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, et al. Increased gut
513 permeability and microbiota change associate with mesenteric fat inflammation and metabolic
514 dysfunction in diet-induced obese mice. *PloS One*. 2012;7(3):e34233.

515 25. Ghosh S, DeCoffe D, Brown K, Rajendiran E, Estaki M, Dai C, et al. Fish Oil Attenuates
516 Omega-6 Polyunsaturated Fatty Acid-Induced Dysbiosis and Infectious Colitis but Impairs LPS
517 Dephosphorylation Activity Causing Sepsis. *Fuss IJ, editor. PLoS ONE*. 2013 Feb 6;8(2):e55468.

518 26. Pulkrabek M, Rhee Y, Gibbs P, Hall C. Flaxseed- and Buckwheat-Supplemented Diets
519 Altered Enterobacteriaceae Diversity and Prevalence in the Cecum and Feces of Obese Mice. *J Diet*
520 *Suppl*. 2017 Nov 2;14(6):667–78.

521 27. Robertson RC, Seira Oriach C, Murphy K, Moloney GM, Cryan JF, Dinan TG, et al.
522 Deficiency of essential dietary n-3 PUFA disrupts the caecal microbiome and metabolome in mice.
523 *Br J Nutr.* 2017 Dec;118(11):959–70.

524 28. Parikh M, Maddaford TG, Austria JA, Aliani M, Neticadan T, Pierce GN. Dietary Flaxseed
525 as a Strategy for Improving Human Health. *Nutrients.* 2019 May 25;11(5).

526 29. Shafie SR, Wanyonyi S, Panchal SK, Brown L. Linseed Components Are More Effective
527 Than Whole Linseed in Reversing Diet-Induced Metabolic Syndrome in Rats. *Nutrients.* 2019 Jul
528 22;11(7):E1677.

529 30. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative Biology of Exercise. *Cell.*
530 2014 Nov 6;159(4):738–49.

531 31. Maillard F, Pereira B, Boisseau N. Effect of High-Intensity Interval Training on Total,
532 Abdominal and Visceral Fat Mass: A Meta-Analysis. *Sports Med Auckl NZ.* 2018 Feb;48(2):269–88.

533 32. Dupuit M, Maillard F, Pereira B, Marcelo LM, Antonio HL, Boisseau N. Effect of high
534 intensity interval training on body composition in women before and after menopause: A meta-
535 analysis. *Exp Physiol.* 2020 Jul 2;

536 33. Yadav DP, Madhusudhan KS, Kedia S, Sharma R, Pratap Mouli V, Bopanna S, et al.
537 Development and validation of visceral fat quantification as a surrogate marker for differentiation of
538 Crohn's disease and intestinal tuberculosis. *J Gastroenterol Hepatol.* 2017 Feb;32(2):420–6.

539 34. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity.
540 1932. *Mt Sinai J Med N Y.* 2000 May;67(3):263–8.

541 35. Serena C, Keiran N, Madeira A, Maymó-Masip E, Ejarque M, Terrón-Puig M, et al. Crohn's
542 Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to
543 Inflammasome Activation. *Stem Cell Rep.* 2017 Oct 10;9(4):1109–23.

544 36. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, et al.
545 Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. *Gastroenterology.* 1999
546 Jul;117(1):73–81.

547 37. Drouet M, Dubuquoy L, Desreumaux P, Bertin B. Visceral fat and gut inflammation. *Nutr*
548 *Burbank Los Angel Cty Calif.* 2012 Feb;28(2):113–7.

549 38. Allen, Higham SM, Mendham AE, Kastelein TE, Larsen PS, Duffield R. The effect of high-
550 intensity aerobic interval training on markers of systemic inflammation in sedentary populations. *Eur*
551 *J Appl Physiol.* 2017 Jun;117(6):1249–56.

552 39. Maillard F, Vazeille E, Sauvanet P, Sirvent P, Bonnet R, Combaret L, et al. Preventive Effect
553 of Spontaneous Physical Activity on the Gut-Adipose Tissue in a Mouse Model That Mimics
554 Crohn's Disease Susceptibility. *Cells.* 2019 Jan 9;8(1):E33.

555 40. Peppler WT, Anderson ZG, MacRae LM, MacPherson REK, Wright DC. Habitual physical
556 activity protects against lipopolysaccharide-induced inflammation in mouse adipose tissue.
557 *Adipocyte.* 2017 Jan 2;6(1):1–11.

558 41. Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S, Dougherty J, et al. Exercise
559 prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity.
560 PloS One. 2014;9(3):e92193.

561 42. Liu, Wang T, Zhou F, Wang Y, Xing J-W, Zhang S, et al. Voluntary exercise prevents
562 colonic inflammation in high-fat diet-induced obese mice by up-regulating PPAR- γ activity.
563 Biochem Biophys Res Commun. 2015 Apr 10;459(3):475–80.

564 43. Taibi A, Ku M, Lin Z, Gargari G, Kubant A, Lepp D, et al. Discriminatory and cooperative
565 effects within the mouse gut microbiota in response to flaxseed and its oil and lignan components. J
566 Nutr Biochem. 2021 Jul 14;98:108818.

567 44. Rickard SE, Orcheson LJ, Seidl MM, Luyengi L, Fong HH, Thompson LU. Dose-dependent
568 production of mammalian lignans in rats and in vitro from the purified precursor secoisolariciresinol
569 diglycoside in flaxseed. J Nutr. 1996 Aug;126(8):2012–9.

570 45. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of
571 total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509.

572 46. Plissonneau C, Capel F, Chassaing B, Dupuit M, Maillard F, Wawrzyniak I, et al. High-
573 Intensity Interval Training and α -Linolenic Acid Supplementation Improve DHA Conversion and
574 Increase the Abundance of Gut Mucosa-Associated Oscillospira Bacteria. Nutrients. 2021 Feb
575 27;13(3):788.

576 47. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-
577 throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012
578 Aug;6(8):1621–4.

579 48. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
580 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat
581 Biotechnol. 2019 Aug;37(8):852–7.

582 49. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-
583 resolution sample inference from Illumina amplicon data. Nat Methods. 2016 Jul;13(7):581–3.

584 50. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An
585 improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of
586 bacteria and archaea. ISME J. 2012 Mar;6(3):610–8.

587 51. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. Fecal
588 lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation.
589 PloS One. 2012;7(9):e44328.

590 52. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, et al. Origins and
591 evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005
592 Feb;81(2):341–54.

593 53. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man.
594 Biochem Soc Trans. 2017 Oct 15;45(5):1105–15.

595 54. Calder PC. Eicosanoids. *Essays Biochem.* 2020 Sep 23;64(3):423–41.

596 55. Buisson A, Vazeille E, Fumery M, Pariente B, Nancey S, Seksik P, et al. Faster and less
597 invasive tools to identify patients with ileal colonization by adherent-invasive *E. coli* in Crohn's
598 disease. *United Eur Gastroenterol J.* 2021 Nov;9(9):1007–18.

599 56. Shim YY, Gui B, Arnison PG, Wang Y, Reaney MJT. Flaxseed (*Linum usitatissimum* L.)
600 bioactive compounds and peptide nomenclature: A review. *Trends Food Sci Technol.* 2014 Jul
601 1;38(1):5–20.

602 57. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, et al. Adherent-invasive
603 *Escherichia coli* in inflammatory bowel disease. *Gut.* 2018 Mar;67(3):574–87.

604 58. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota.
605 *Environ Microbiol.* 2017;19(1):29–41.

606 59. Mukhopadhyay I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play?
607 *Nat Rev Gastroenterol Hepatol.* 2012 Feb 21;9(4):219–30.

608 60. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-Induced Obesity Is Linked to Marked
609 but Reversible Alterations in the Mouse Distal Gut Microbiome. *Cell Host Microbe.* 2008 Apr
610 17;3(4):213–23.

611 61. Yu H-N, Zhu J, Pan W, Shen S-R, Shan W-G, Das UN. Effects of fish oil with a high content
612 of n-3 polyunsaturated fatty acids on mouse gut microbiota. *Arch Med Res.* 2014 Apr;45(3):195–
613 202.

614 62. Valle M, Mitchell PL, Pilon G, St-Pierre P, Varin T, Richard D, et al. Cholecalciferol
615 Supplementation Does Not Prevent the Development of Metabolic Syndrome or Enhance the
616 Beneficial Effects of Omega-3 Fatty Acids in Obese Mice. *J Nutr.* 2021 May 11;151(5):1175–89.

617 63. Zhu, Bi Z, Yang C, Guo Y, Yuan J, Li L, et al. Effects of different doses of omega-3
618 polyunsaturated fatty acids on gut microbiota and immunity. *Food Nutr Res.* 2021;65.

619 64. Gallè F, Valeriani F, Cattaruzza MS, Gianfranceschi G, Liguori R, Antinozzi M, et al.
620 Mediterranean Diet, Physical Activity and Gut Microbiome Composition: A Cross-Sectional Study
621 among Healthy Young Italian Adults. *Nutrients.* 2020 Jul 21;12(7):E2164.

622 65. Carreño D, Toral PG, Pinloche E, Belenguer A, Yáñez-Ruiz DR, Hervás G, et al. Rumen
623 bacterial community responses to DPA, EPA and DHA in cattle and sheep: A comparative in vitro
624 study. *Sci Rep.* 2019 Aug 14;9(1):11857.

625 66. Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced
626 Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's
627 Disease. *Digestion.* 2016;93(1):59–65.

628 67. Li XZ, Park BK, Shin JS, Choi SH, Smith SB, Yan CG. Effects of dietary linseed oil and
629 propionate precursors on ruminal microbial community, composition, and diversity in Yanbian
630 yellow cattle. *PloS One.* 2015;10(5):e0126473.

68. Landete JM, Arqués J, Medina M, Gaya P, de Las Rivas B, Muñoz R. Bioactivation of Phytoestrogens: Intestinal Bacteria and Health. *Crit Rev Food Sci Nutr*. 2016 Aug 17;56(11):1826–43.
69. Lagkouvardos I, Kläring K, Heinzmann SS, Platz S, Scholz B, Engel K-H, et al. Gut metabolites and bacterial community networks during a pilot intervention study with flaxseeds in healthy adult men. *Mol Nutr Food Res*. 2015 Aug;59(8):1614–28.
70. Brito AF, Zang Y. A Review of Lignan Metabolism, Milk Enterolactone Concentration, and Antioxidant Status of Dairy Cows Fed Flaxseed. *Mol Basel Switz*. 2018 Dec 22;24(1):E41.
71. Lampe JW, Kim E, Levy L, Davidson LA, Goldsby JS, Miles FL, et al. Colonic mucosal and exfoliome transcriptomic profiling and fecal microbiome response to a flaxseed lignan extract intervention in humans. *Am J Clin Nutr*. 2019 Aug;110(2):377–90.
72. Clavel T, Lippman R, Gavini F, Doré J, Blaut M. *Clostridium saccharogumia* sp. nov. and *Lactonifactor longoviformis* gen. nov., sp. nov., two novel human faecal bacteria involved in the conversion of the dietary phytoestrogen secoisolariciresinol diglucoside. *Syst Appl Microbiol*. 2007 Jan;30(1):16–26.
73. Schogor ALB, Huws SA, Santos GTD, Scollan ND, Hauck BD, Winters AL, et al. Ruminant *Prevotella* spp. may play an important role in the conversion of plant lignans into human health beneficial antioxidants. *PloS One*. 2014;9(4):e87949.
74. Beaud D, Tailliez P, Anba-Mondoloni J. Genetic characterization of the beta-glucuronidase enzyme from a human intestinal bacterium, *Ruminococcus gnavus*. *Microbiol Read Engl*. 2005 Jul;151(Pt 7):2323–30.
75. Fuentealba C, Figuerola F, Estévez AM, Bastías JM, Muñoz O. Bioaccessibility of lignans from flaxseed (*Linum usitatissimum* L.) determined by single-batch in vitro simulation of the digestive process. *J Sci Food Agric*. 2014 Jul;94(9):1729–38.
76. Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ, Clardy J. *Ruminococcus gnavus*, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. *Proc Natl Acad Sci U S A*. 2019 Jun 25;116(26):12672–7.
77. Petersen LM, Bautista EJ, Nguyen H, Hanson BM, Chen L, Lek SH, et al. Community characteristics of the gut microbiomes of competitive cyclists. *Microbiome*. 2017 10;5(1):98.
78. Allen, Berg Miller ME, Pence BD, Whitlock K, Nehra V, Gaskins HR, et al. Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6J mice. *J Appl Physiol Bethesda Md* 1985. 2015 Apr 15;118(8):1059–66.

Table 1. Macronutrients (% kcal/100 g) in the three high-fat diets supplemented with linseed (HFD-LS-O and HFD-LS-E) or not (HFD) and their n-6/n-3 PUFAs ratio

	HFD (<i>n</i> = 16)	HFD-LS-O (<i>n</i> = 16)	HFD-LS-E (<i>n</i> = 16)
Proteins (%kcal)	19.0	19.0	19.5
Carbohydrates (%kcal)	40.6	40.6	40.1
Lipids (%kcal)	40.4	40.4	40.4
SFAs (% of lipid fraction)	40.0	40.0	36.7
MUFAs (%)	44.1	44.3	41.0
PUFAs(%)	15.8	15.8	20.6
LA (C18:2 n-6) (%)	1.0	3.6	5.2
ALA (C18:3 n-3) (%)	14.8	12.1	15.4
kcal/100 g	468.4	468.4	460.4
n-6/n-3 PUFA ratio	14.8	3.3	3.0

HFD (High-fat diet, *n* = 16), HFD-LS-O (linseed oil-supplemented HFD, *n* = 16) and HFD-LS-E (extruded linseed-supplemented HFD, *n* = 16). SFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; LA: linoleic acid; ALA: α -linolenic acid

685 **Table 2. Diet composition**

	HFD (<i>n</i> = 16)		HFD-LS-O (<i>n</i> = 16)		HFD-LS-E (<i>n</i> = 16)	
	w/w (%)	kcal/100g	w/w (%)	kcal/100g	w/w (%)	kcal/100g
Casein	22	88	22	88	21	84
L-Cystine	0.3	1.2	0.3	1.2	0.3	1.2
Sunflower oil	2	18	0.99	8.91	2	18
Lard	19	171	19	171	17	153
Linseed oil			1.01	9.09		
Extruded linseed					6	15.12
Starch	17	68	17	68	15	60
Maltodextrin	7	28	7	28	7	28
Sucrose	22.55	90.2	22.55	90.2	22	88
Cellulose	5		5		4.55	
AIN93M	4		4		4	
AIN93Vx	1	4	1	4	1	4
Choline	0.15		0.15		0.15	
Total	100	468.4	100	468.4	100	460.44

686 HFD (High-fat diet, *n* = 16), HFD-LS-O (linseed oil-supplemented HFD, *n* = 16) and HFD-LS-E
687 (extruded linseed-supplemented HFD, *n* = 16).

688

689

690

691

692

693

694

695

696

697

698

699

Table 3. Fecal acetate, butyrate and propionate (μmol.g⁻¹ feces).

	HFD (<i>n</i> = 16)	HFD-LS-O (<i>n</i> = 16)	HFD-LS-E (<i>n</i> = 16)	<i>p</i>
Acetate	10.6 ± 4.7	11.2 ± 5.9	13.5 ± 4.4	0.11
Butyrate	0.18 ± 0.3	0.16 ± 0.2	0.35 ± 0.3	0.13
Propionate	2.22 ± 1.2	2.1 ± 0.7	2.7 ± 0.7	0.073
Total SCFAs	12.8 ± 5.8	13.3 ± 6.5	16.2 ± 4.8	0.09

HFD (High-fat diet, *n* = 16), HFD-LS-O (linseed oil-supplemented HFD, *n* = 16), HFD-LS-E (extruded linseed-supplemented HFD, *n* = 16). SCFAs: short chain fatty acids; Total SCFAs: acetate + butyrate + propionate.

Figure 1. Study protocol. Eight-week-old mice were randomly divided in three groups that performed voluntary wheel running: HFD (High-fat diet, n = 16), HFD-LS-O (linseed oil-supplemented-HFD, n = 16) and HFD-LS-E (extruded linseed-supplemented-HFD, n = 16). The distance covered by wheel running was recorded continuously for 12 weeks. At the end of week 12 (W12), 1% dextran sulfate sodium (DSS) was added in the water of mice and after 3 days, mice were orally challenged with the adherent-invasive E.coli (AIEC) strain LF82 (once) and euthanized at day 7 after the challenge. Pair-feeding was performed during the first 12 weeks.

Figure 2. Macronutrient composition (%energy/100g) of linseed oil (Vigean®, France) and extruded linseed (Tradi-Mega; Tradilin, Patent n°FR1760984) used as supplements.

Figure 3. Effect of 12 weeks of voluntary physical activity and HFD diet, supplemented or nor with linseed, on the cumulative food intake (kcal) (A), mean distance covered by wheel running (km.day⁻¹) (B), body weight changes (%) (C), weight gain (week 12 – week 1): fat mass (FM) (g) and fat-free mass (FFM) (g) (D), mesenteric adipose tissue (%FM) (E), epididymal adipose tissue (%FM) (F) and LA/ALA ratio in mesenteric adipose tissue (G) in the three groups. Data are the mean ± SEM (A, C) or mean ± SD (B, D, E, F and G). LA: linoleic acid; ALA: α-linolenic acid

Figure 4. Weight change (%) after the oral challenge with the AIEC strain LF82 (A). Fecal lipocalin-2 concentration (μg.g⁻¹ feces) at day 1 (D1) and D6 post-challenge (B), and correlation between lipocalin-2 concentration (μg.g⁻¹ feces) at D3 post-challenge and mean wheel running distance (km) per day (C) in the three groups. Intestinal permeability was assessed by measuring FITC-dextran 4 kDa in the serum 5 hours after intragastric administration of 7.5 mg FITC-dextran (n = 16 mice/group) at week 12, before the AIEC challenge (D). Plasma concentration (ng.ml⁻¹) of active LPS 7 days post-AIEC pathobiont challenge (E). HFD-LS-O: pink triangles; HFD-LS-E green circles. *p<0.05, ****p<0.0001

Figure 5. Mucosa-associated microbiota composition analyzed by 16S rRNA gene sequencing in DNA samples (Illumina MiSeq system) from HFD (n = 14), HFD-LS-O (n = 15) and HFD-LS-E (n = 15) colon samples collected at day 7 after oral challenge with the AIEC strain LF82. Operational taxonomic units (OTUs) with a rarefaction depth of 6884 sequences (A), observed OTUs (B), Shannon index (C), evenness (D), phylogenetic diversity (E), weighted (F) and unweighted Unifrac analysis (G). *p<0.05, **p<0.01 and ***p<0.001

Figure 6. Composition of the mucosa-associated microbiota. Phylum distribution (%) (A), Firmicutes/Proteobacteria ratio (B), and relative abundance (%) of specific bacterial species in the mucosa-associated microbiota: *Clostridiales* (C), *Paraprevotella* spp. (D), *Ruminococcus* (E) and *Prevotella* (F). Colon samples from HFD (n = 14), HFD-LS-O (n = 15) and HFD-LS-E (n = 15) mice collected at day 7 post-challenge with the AIEC strain LF82. *p<0.05 **p<0.01, ***p<0.001, ****p<0.0001

Figure 7. Fecal butyrate concentration (μmol.g⁻¹) (A), percentage of mice with detectable fecal butyrate in each group (B), and correlation between fecal butyrate concentration and Firmicutes/Proteobacteria ratio (C). HFD (n = 14), HFD-LS-O (n = 15) and HFD-LS-E (n = 15). ****p<0.0001




Figure 1. Study protocol. Eight-week-old mice were randomly divided in three groups that performed voluntary wheel running: HFD (High-fat diet, $n = 16$), HFD-LS-O (linseed oil-supplemented-HFD, $n = 16$) and HFD-LS-E (extruded linseed-supplemented-HFD, $n = 16$). The distance covered by wheel running was recorded continuously for 12 weeks. At the end of week 12 (W12), 1% dextran sulfate sodium (DSS) was added in the water of mice and after 3 days, mice were orally challenged with the adherent-invasive *E.coli* (AIEC) strain LF82 (once) and euthanized at day 7 after the challenge. Pair-feeding was performed during the first 12 weeks.




Figure 2. Macronutrient composition (%energy/100g) of linseed oil (Vigean®, France) and extruded linseed (Tradi-Mega; Tradilin, Patent n°FR1760984) used as supplements.




Figure 3. Effect of 12 weeks of voluntary physical activity and HFD diet, supplemented or nor with linseed, on the cumulative food intake (kcal) (A), mean distance covered by wheel running (km.day⁻¹) (B), body weight changes (%) (C), weight gain (Week 12 – week 1): fat mass (FM) (g) and fat-free mass (FFM) (g) (D), mesenteric adipose tissue (%FM) (E), epididymal adipose tissue (%FM) (F) and LA/ALA ratio in mesenteric adipose tissue (G) in the three groups. Data are the mean \pm SEM (A, C) or mean \pm SD (B, D, E, F and G). LA : linoleic acid; ALA: α -linolenic acid




Figure 4. Weight change (%) after the oral challenge with the AIEC strain LF82 (A). Fecal lipocalin-2 concentration ($\mu\text{g.g}^{-1}$ feces) at day 1 (D1) and D6 post-challenge (B), and correlation between lipocalin-2 concentration ($\mu\text{g.g}^{-1}$ feces) at D3 post-challenge and mean wheel running distance (km) per day (C) in the three groups. Intestinal permeability was assessed by measuring FITC-dextran 4 kDa in the serum 5 hours after intragastric administration of 7.5 mg FITC-dextran ($n = 16$ mice/group) at week 12, before the AIEC challenge (D). Plasma concentration (ng.mL^{-1}) of active LPS 7 days post-AIEC pathobiont challenge (E). HFD-LS-O: pink triangles; HFD-LS-E green circles. * $p < 0.05$, **** $p < 0.0001$




Figure 5. Mucosa-associated microbiota composition analyzed by 16S rRNA gene sequencing in DNA samples (Illumina MiSeq system) from HFD ($n = 14$), HFD-LS-O ($n = 15$) and HFD-LS-E ($n = 15$) colon samples collected at day 7 after oral challenge with the AIEC strain LF82. Operational taxonomic units (OTUs) with a rarefaction depth of 6884 sequences (A), observed OTUs (B), Shannon index (C), evenness (D), phylogenetic diversity (E), weighted (F) and unweighted Unifrac analysis (G). * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$




Figure 6. Composition of the mucosa-associated microbiota. Phylum distribution (%) (A), Firmicutes/Proteobacteria ratio (B), and relative abundance (%) of specific bacterial species in the mucosa-associated microbiota: *Clostridiales* (C), *Paraprevotella* spp. (D), *Ruminococcus* (E) and *Prevotella* (F). Colon samples from HFD ($n = 14$), HFD-LS-O ($n = 15$) and HFD-LS-E ($n = 15$) mice collected at day 7 post-challenge with the AIEC strain LF82. * $p < 0.05$ ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Figure 7. Fecal butyrate concentration ($\mu\text{mol.g}^{-1}$) (A), percentage of mice with detectable fecal butyrate in each group (B), and correlation between fecal butyrate concentration and *Firmicutes/Proteobacteria* ratio (C). HFD ($n = 14$), HFD-LS-O ($n = 15$) and HFD-LS-E ($n = 15$). **** $p < 0.0001$